Cargando...

A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS: Patients received vorinostat orally once daily on days 1–14...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Schelman, William R., Traynor, Anne M., Holen, Kyle D., Kolesar, Jill M., Attia, Steven, Hoang, Tien, Eickhoff, Jens, Jiang, Zhisheng, Alberti, Dona, Marnocha, Rebecca, Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Espinoza-Delgado, Igor, Wright, John J., Wilding, George, Bailey, Howard H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901262/
https://ncbi.nlm.nih.gov/pubmed/24114121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0029-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!